A brief application for a new drug "non-Lotte flat release tablets" declared by the FDA of Ling Pharmaceuticals has been approved

recently, Eling Pharmaceuticals announced that theCompany(wholly-owned subsidiary Ofling Wanzhou InternationalPharmaceutical(to theFDA(declared "non-Lotte flat release"new drug(brief application has been approved)theproduct(the third varieties of The Industry to obtain FDA approval, and the company's first export of slow-release preparationsabout non-lotty flat release tablets
non-lotty flat release tablets are a dihydroquine calcium channel antagonist for the treatment of hypertension (can be used alone or with other antihypertensivedrugs(combined use)according to the , the overall market for medical medical in China in 2017 was RMB2,023 million, of which sales of reprieve tablets amounted to RMB1,634 million according to the comprehensive database, including the original research manufacturers (for AstraZeneca), currently has non-Loti flat release film production approval of the manufacturers have 6, to Ling Pharmaceutical's non-Loti flat release film is not listed in the country From the product competitive pattern, the original research manufacturer AstraZeneca with more than 80% of the market share in the first place, Changzhou four pharmaceutical products with 8.77% of the market share immediately followed according to the announcement, the non-Lotdi flat release tablets of Eling Pharmaceuticals are the third approval number approved by the company in the United States and the first approval number for the release of the preparation, according to the announcement